May 12, 2014 – Munich Germany

Systasy Bioscience GmbH and Sygnis AG closed a patent transfer deal today. A patent transfer agreement for Double Switch technology was signed. Systasy intends to integrate this technology within their EXTassay platformand offer a novel assay service termed as targetPROFILER. Systasy is very enthusiastic about the novel opportunities that this technology transfer will bring to their portfolio of services in drug discovery domain. Combined with their multiplexable EXTassays, the splitSENSOR offers a rather comprehensive understanding of the signaling pathways and protein interactions upon receptor activation via a stimuli (i.e., Ligand/Drugs).

Press release from SYGINS AG